University General Hospital Of Heraklion
- Address
- lock Available on a paid plan
Oncology and Solid Tumors
The University General Hospital Of Heraklion is highly active in medical oncology, with trials focused on major neoplasms such as breast cancer, non-small cell lung cancer, small cell lung cancer, and gastric and colorectal cancers. Research here is largely aimed at testing new cancer treatments, improving disease control, and lowering the risk of recurrence or progression.
- Studies in advanced and early-stage breast cancer, including hormone receptor-positive and HER2-related disease
- Trials in non-small cell lung cancer and small cell lung cancer, including targeted and immunotherapy approaches
- Research in other solid tumors, including metastatic and treatment-resistant cancers
These trials reflect a strong emphasis on evaluating treatment effectiveness and expanding options for patients with difficult-to-treat cancers.
Immune-Mediated and Inflammatory Diseases
A major part of the site’s research portfolio addresses immune system diseases and chronic inflammatory conditions, especially Crohn’s disease, ulcerative colitis, systemic lupus erythematosus, psoriatic arthritis, and rheumatoid arthritis. The studies are designed to improve symptom control, reduce flares, and assess longer-term safety of emerging therapies.
- Crohn’s disease and ulcerative colitis trials focused on better control of bowel inflammation
- Systemic lupus erythematosus research examining new options for disease activity and tolerability
- Studies in psoriasis, psoriatic arthritis, and related autoimmune conditions
At this site, the goal is often to find therapies that can offer more durable relief for patients living with chronic immune-mediated disease.
Kidney, Cardiovascular, and Metabolic Research
The hospital also conducts extensive trials in cardiovascular diseases, chronic kidney disease, and nutritional and metabolic diseases. Key areas include hypertension, atherosclerotic cardiovascular disease, lipoprotein(a) elevation, proteinuria, and several forms of glomerular disease. Many of these studies aim to slow organ damage and reduce long-term cardiovascular risk.
- Chronic kidney disease and proteinuria, including studies on preserving kidney function
- Hypertension and broader cardiovascular risk reduction
- Research in IgA nephropathy, complement-mediated kidney disease, and related renal disorders
These trials combine prevention and treatment goals, with a strong focus on improving long-term outcomes for patients with overlapping kidney and heart disease.
Respiratory and Pulmonary Disorders
Another important research area at University General Hospital Of Heraklion involves respiratory tract diseases and progressive lung conditions such as idiopathic pulmonary fibrosis, pulmonary sarcoidosis, COPD, asthma, and progressive pulmonary fibrosis. These studies are generally aimed at evaluating new therapies that may reduce inflammation, improve breathing, and slow disease worsening.
- Idiopathic pulmonary fibrosis and progressive fibrosing lung disease
- Asthma and COPD, including symptom control and rescue treatment research
- Pulmonary sarcoidosis and other inflammatory lung disorders
The site’s pulmonary trials are centered on finding better ways to preserve lung function and improve daily quality of life.
Hematology, Immunology, and Infectious Diseases
The site supports a broad range of studies in hemic and lymphatic diseases, virus diseases, and bacterial infections. Research includes acute leukemias, neutropenia, sepsis, candidemia, and difficult viral infections in immunocompromised patients. These trials often aim to improve survival, prevent complications, and strengthen infection control.
- Acute lymphoblastic leukemia and acute myeloid leukemia studies
- Sepsis and serious hospital-related infections
- Research on resistant viral and fungal infections in vulnerable patients
This area reflects a strong interest in both cancer-related blood disorders and the management of severe infections in high-risk groups.
Neurology, Psychiatry, and Other Specialized Conditions
Beyond its major disease programs, the site also conducts trials in nervous system diseases and mental disorders, including Alzheimer’s disease-related agitation and psychosis, as well as selected rare and complex conditions such as Fabry disease, amyloidosis, and ophthalmic diseases. These studies are intended to improve symptoms, refine diagnosis, and explore new treatment options for conditions with limited current choices.
- Alzheimer’s disease-related behavioral symptoms and major depressive disorder
- Rare diseases such as Fabry disease and amyloidosis
- Eye diseases including age-related macular degeneration
These projects add breadth to the site’s portfolio and show its involvement in both common chronic illness and less frequent specialized disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 24 therapeutic areas and 15 of 364 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 357 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 60 by active trials.
- 1AstraZeneca AB9active
lock +59 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.15trials
lock +32 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University General Hospital Of Heraklion
lock Showing 1 of 231 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN) | Novartis Pharma AG | Phase III | Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 364 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 14 | Unknown | 2015-11-06 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
